Komori
Occurring Fact190AChordia Therapeutics Inc.Pharmaceuticals

Notice Regarding Completion of Patient Enrollment in the Initial Expansion Cohort of Rogocekib

In the U.S. Phase 1/2 clinical trial of rogocekib, enrollment of all 28 planned cases in the initial expansion (IE) cohort and initial dosing of the last subject have been completed. The company will proceed with analysis of the IE cohort data and preparations to initiate the additional expansion (AE) cohort.

Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
28
cases
Wording
Definitive
How definitive the wording is.

Completion of Case Enrollment in the Rogocekib Initial Expansion Cohort

Subject Entity

Chordia Therapeutics, Inc.

Target Locations / Products

Rogocekib (CTX-712) in a U.S. Phase 1/2 clinical trial, initial expansion cohort (IE cohort). The target patients are those with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

Occurrence24 September 2026 (disclosure date; no specific enrollment completion date was separately stated)
This disclosure09/24/2026
Outlook

The company will analyze the data obtained from the IE cohort and proceed with preparations to initiate the AE cohort. It will steadily advance its development plan, giving the safety of subjects the highest priority.

Planned follow-up disclosure

The company will promptly announce any further developments that should be disclosed.

Event that occurred
ItemDetails
Event nameCompletion of Case Enrollment in the Rogocekib Initial Expansion Cohort
Date of occurrence24 September 2026 (disclosure date; no specific enrollment completion date was separately stated)
Subject EntityChordia Therapeutics, Inc.
Target Locations / ProductsRogocekib (CTX-712) in a U.S. Phase 1/2 clinical trial, initial expansion cohort (IE cohort). The target patients are those with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
OutlookThe company will analyze the data obtained from the IE cohort and proceed with preparations to initiate the AE cohort. It will steadily advance its development plan, giving the safety of subjects the highest priority.
Planned follow-up disclosureThe company will promptly announce any further developments that should be disclosed.
Items this document does not state (19)
Date recognized / date notice receivedCauseAmount of Impact on Business PerformanceAccounting period in which recognizedImpact on Earnings ForecastType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the change

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This represents progress in line with the company's development plan.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Completion of Patient Enrollment in the Initial Expansion Cohort of Rogocekib | Chordia Therapeutics Inc. (190A) timely disclosure | Komori